coronavirus antibody Archives - Halberd Corporation

Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By Admin|2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Oct 19 2020

Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

By Admin|2020-10-19T12:43:39-04:00October 19th, 2020|Featured, Investor News, News|0 Comments

Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. ...

Oct 13 2020

Arizona State University/Halberd Develop Antibody Against Covid-19

By Admin|2020-10-12T20:32:43-04:00October 13th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. ...